Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Granules India has reported consolidated financial results for the period ended December 31, 2021
Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021
Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
The partnership includes multiple collaboration areas and is an important milestone for bringing cost-competitive biobased products to the market, with applications in the pharmaceutical, agricultural, cosmetics and personal care, and automotive industries
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
The campaign aims to bring back focus on leprosy case detection, treatment and rehabilitation; especially in the context of neglect brought in by Covid-19 pandemic
Subscribe To Our Newsletter & Stay Updated